DS-3939a

· Daiichi Sankyo

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for DS-3939a, covering 2026-04-20 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors [Phase 1, Phase 2]